Chronic activation of coagulation is one of the features of sickle cell disease (SCD). Increased tissue factor expression, phosphatidylserine exposure, thrombin generation and fibrinolysis, as well as decreased levels of natural anticoagulants have been reported in SCD patients and in the mouse models of SCD. Consistent with this, patients with SCD are prone to develop thrombotic complications. In addition, the altered morphology of sickle red blood cells (RBC) may also alter the properties and dynamics of clot formation in SCD patients. Clinical data and results from animal models have revealed complex interactions between coagulation, chronic hemolysis, and inflammation suggesting that activation of coagulation may contribute to the pathophysiology of SCD.
QuinnCT. Minireview: Clinical severity in sickle cell disease: The challenges of definition and prognostication. Experimental Biology and Medicine (Maywood, NJ). 2016;241(7):679–88.
3.
ConranN, Franco-PenteadoCF, CostaFF. Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion. Hemoglobin. 2009;33(1):1–16.
4.
KatoGJ, GladwinMT, SteinbergMH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Reviews. 2007;21(1):37–47.
5.
AtagaKI, BrittainJE, DesaiP, MayR, JonesS, DelaneyJ, et al. Association of coagulation activation with clinical complications in sickle cell disease. PLoS One. 2012;7(1):e29786.
6.
ChantrathammachartP, MackmanN, SparkenbaughE, WangJG, PariseLV, KirchhoferD, et al. Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood. 2012;120(3):636–46.
7.
KennedyJRAttenuating a sickle cell crisis with annexin V. Med Hypotheses. 2015;84(5):434–6.
8.
SparkenbaughEM, ChantrathammachartP, WangS, JonasW, KirchhoferD, GailaniD, et al. Excess of heme induces tissue factor-dependent activation of coagulation in mice. Haematologica. 2015;100(3):308–14.
9.
WhelihanMF, LimMY, KeyNS. Red blood cells and thrombin generation in sickle cell disease. Thromb Res. 2014;133(Suppl 1):S52–3.
10.
WhelihanMF, LimMY, MooberryMJ, PiegoreMG, IlichA, WoguA, et al. Thrombin generation and cell-dependent hypercoagulability in sickle cell disease. J Thromb Haemost. 2016;14(10):1941–52.
11.
ArumugamPI, MullinsES, ShanmukhappaSK, MoniaBP, LobergA, ShawMA, et al. Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice. Blood. 2015;126(15):1844–55.
12.
TomerA, HarkerLA, KaseyS, EckmanJR. Thrombogenesis in sickle cell disease. The Journal of Laboratory and Clinical Medicine. 2001;137(6):398–407.
13.
WestermanMP, GreenD, Gilman-SachsA, BeamanK, FreelsS, BoggioL, et al. Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. The Journal of Laboratory and Clinical Medicine. 1999;134(4):352–62.
14.
FamoduAA, OduwaD. Platelet count and platelet factor 3 (PF-3) availability in sickle cell disease. British Journal of Biomedical Science. 1995;52(4):323–4.
15.
AtagaKI, OrringerEP. Hypercoagulability in sickle cell disease: A curious paradox. The American Journal of Medicine. 2003;115(9):721–8.
16.
SettyBN, RaoAK, StuartMJ. Thrombophilia in sickle cell disease: The red cell connection. Blood. 2001;98(12):3228–33.
17.
BucknerTW, KeyNS. Venous thrombosis in blacks. Circulation. 2012;125(6):837–9.
18.
SparkenbaughE, PawlinskiR. Interplay between coagulation and vascular inflammation in sickle cell disease. British Journal of Haematology. 2013;162(1):3–14.
19.
ChenG, ZhangD, FuchsTA, ManwaniD, WagnerDD, FrenettePS. Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood. 2014;123(24):3818–27.
20.
FuchsTA, BrillA, DuerschmiedD, SchatzbergD, MonestierM, MyersDDJr, et al. Extracellular DNA traps promote thrombosis. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(36):15880–5.
21.
NaikRP, StreiffMB, HaywoodCJr, NelsonJA, LanzkronS. Venous thromboembolism in adults with sickle cell disease: A serious and under-recognized complication. The American Journal of Medicine. 2013;126(5):443–9.
22.
BrunsonA, LeiA, RosenbergAS, WhiteRH, KeeganT, WunT. Increased incidence of VTE in sickle cell disease patients: Risk factors, recurrence and impact on mortality. British Journal of Haematology. 2017;178(2):319–26.
23.
NaikRP, StreiffMB, HaywoodCJr, SegalJB, LanzkronS. Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease. J Thromb Haemost. 2014;12(12):2010–6.
24.
MackmanN. Triggers, targets and treatments for thrombosis. Nature. 2008;451(7181):914–8.
25.
SteinPD, BeemathA, MeyersFA, SkafE, OlsonRE. Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. The American Journal of Medicine. 2006;119(10):897e7–11.
26.
CinesDB, LebedevaT, NagaswamiC, HayesV, MassefskiW, LitvinovRI, et al. Clot contraction: Compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. Blood. 2014;123(10):1596–603.
27.
StraussHMD, RollinsMR, WeiselJW, LamWA. Clot contraction-mediated erythrocyte packing is significantly altered in sickle cell disease. Blood. 2015;126:215.
28.
TutwilerV, LitvinovRI, LozhkinAP, PeshkovaAD, LebedevaT, AtaullakhanovFI, et al. Kinetics and mechanics of clot contraction are governed by the molecular and cellular composition of the blood. Blood. 2016;127(1):149–59.
29.
MackmanN. New insights into the mechanisms of venous thrombosis. The Journal of Clinical Investigation. 2012;122(7):2331–6.
30.
PawlinskiR, PedersenB, ErlichJ, MackmanN. Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: Lessons from low tissue factor mice. Thrombosis and Haemostasis. 2004;92(3):444–50.
31.
CrawleyJT, ZanardelliS, ChionCK, LaneDA. The central role of thrombin in hemostasis. J Thromb Haemost. 2007;5(Suppl 1):95–101.
32.
FurieB. Pathogenesis of thrombosis. Hematology/the Education Program of the American Society of Hematology. 2009:255–8.
33.
AlemanMM, ByrnesJR, WangJ, TranR, LamWA, Di PaolaJ, et al. Factor XIII activity mediates red blood cell retention in venous thrombi. The Journal of Clinical Investigation. 2015;124(8):3590–600.
34.
ChapinJC, HajjarKA. Fibrinolysis and the control of blood coagulation. Blood Reviews. 2015;29(1):17–24.
35.
van BeersEJ, SchaapMC, BerckmansRJ, NieuwlandR, SturkA, van DoormaalFF, et al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica. 2009;94(11):1513–9.
36.
NoubouossieDC, LePQ, RozenL, DebaugniesF, FersterA, DemulderA. Evaluation of the procoagulant activity of endogenous phospholipids in the platelet-free plasma of children with sickle cell disease using functional assays. Thromb Res. 2012;130(2):259–64.
37.
NoubouossieDF, LePQ, CorazzaF, DebaugniesF, RozenL, FersterA, et al. Thrombin generation reveals high procoagulant potential in the plasma of sickle cell disease children. American Journal of Hematology. 2012;87(2):145–9.
38.
PetersM, PlaatBE, ten CateH, WoltersHJ, WeeningRS, BrandjesDP. Enhanced thrombin generation in children with sickle cell disease. Thrombosis and Haemostasis. 1994;71(2):169–72.
39.
PasztyC, BrionCM, ManciE, WitkowskaHE, StevensME, MohandasN, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science (New York, NY). 1997;278(5339):876–8.
40.
WuLC, SunCW, RyanTM, PawlikKM, RenJ, TownesTM. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood. 2006;108(4):1183–8.
41.
LimMY, AtagaKI, KeyNS. Hemostatic abnormalities in sickle cell disease. Current Opinion in Hematology. 2013;20(5):472–7.
42.
KeyNS, SlungaardA, DandeletL, NelsonSC, MoertelC, StylesLA, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood. 1998;91(11):4216–23.
43.
EdgingtonTS, MackmanN, BrandK, RufW. The structural biology of expression and function of tissue factor. Thrombosis and Haemostasis. 1991;66(1):67–79.
44.
OsterudB. Tissue factor: A complex biological role. Thrombosis and Haemostasis. 1997;78(1):755–8.
45.
MackmanN, TilleyRE, KeyNS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27(8):1687–93.
46.
RagabSM, SolimanMA. Tissue factor-positive monocytes expression in children with sickle cell disease: Clinical implication and relation to inflammatory and coagulation markers. Blood Coagul Fibrinolysis. 2016;27(8):862–9.
47.
SettyBN, KeyNS, RaoAK, Gayen-BetalS, KrishnanS, DampierCD, et al. Tissue factor-positive monocytes in children with sickle cell disease: Correlation with biomarkers of haemolysis. British Journal of Haematology. 2012;157(3):370–80.
48.
SoloveyA, KollanderR, ShetA, MilbauerLC, ChoongS, Panoskaltsis-MortariA, et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood. 2004;104(3):840–6.
49.
SoloveyA, GuiL, KeyNS, HebbelRP. Tissue factor expression by endothelial cells in sickle cell anemia. The Journal of Clinical Investigation. 1998;101(9):1899–904.
50.
SparkenbaughEM, ChantrathammachartP, ChandarajotiK, MackmanN, KeyNS, PawlinskiR. Thrombin-independent contribution of tissue factor to inflammation and cardiac hypertrophy in a mouse model of sickle cell disease. Blood. 2016;127(10):1371–3.
51.
TakemotoM, LiaoJK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21(11):1712–9.
52.
HoppeC, KuypersF, LarkinS, HagarW, VichinskyE, StylesL. A pilot study of the short-term use of simvastatin in sickle cell disease: Effects on markers of vascular dysfunction. British Journal of Haematology. 2011;153(5):655–63.
53.
SoloveyA, KollanderR, MilbauerLC, AbdullaF, ChenY, KelmRJJr, et al. Endothelial nitric oxide synthase and nitric oxide regulate endothelial tissue factor expression in vivo in the sickle transgenic mouse. American Journal of Hematology. 2010;85(1):41–5.
54.
KollanderR, SoloveyA, MilbauerLC, AbdullaF, KelmRJJr, HebbelRP. Nuclear factor-kappa B (NFkappaB) component p50 in blood mononuclear cells regulates endothelial tissue factor expression in sickle transgenic mice: Implications for the coagulopathy of sickle cell disease. Translational Research: The Journal of Laboratory and Clinical Medicine. 2010;155(4):170–7.
55.
FranckPF, BeversEM, LubinBH, ComfuriusP, ChiuDT, Op den KampJA, et al. Uncoupling of the membrane skeleton from the lipid bilayer. The cause of accelerated phospholipid flip-flop leading to an enhanced procoagulant activity of sickled cells. The Journal of Clinical Investigation. 1985;75(1):183–90.
56.
SegawaK, NagataS. An apoptotic ‘eat me’ signal: Phosphatidylserine exposure. Trends in Cell Biology. 2015;25(11):639–50.
57.
LubinB, ChiuD, BastackyJ, RoelofsenB, Van DeenenLL. Abnormalities in membrane phospholipid organization in sickled erythrocytes. The Journal of Clinical Investigation. 1981;67(6):1643–9.
58.
TaitJF, GibsonD. Measurement of membrane phospholipid asymmetry in normal and sickle-cell erythrocytes by means of annexin V binding. The Journal of Laboratory and Clinical Medicine. 1994;123(5):741–8.
59.
de JongK, LarkinSK, StylesLA, BookchinRM, KuypersFA. Characterization of the phosphatidylserine-exposing subpopulation of sickle cells. Blood. 2001;98(3):860–7.
60.
ChoeHR, SchlegelRA, RubinE, WilliamsonP, WestermanMP. Alteration of red cell membrane organization in sickle cell anaemia. British Journal of Haematology. 1986;63(4):761–73.
61.
YasinZ, WittingS, PalascakMB, JoinerCH, RucknagelDL, FrancoRS. Phosphatidylserine externalization in sickle red blood cells: Associations with cell age, density, and hemoglobin F. Blood. 2003;102(1):365–70.
62.
BrigliaM, Antonia RossiM, FaggioC. Eryptosis: Ally or Enemy. Current Medicinal Chemistry. 2016.
63.
KuypersFA, LewisRA, HuaM, SchottMA, DischerD, ErnstJD, et al. Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V. Blood. 1996;87(3):1179–87.
64.
WoodBL, GibsonDF, TaitJF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: Flow-cytometric measurement and clinical associations. Blood. 1996;88(5):1873–80.
65.
SemeraroF, AmmolloCT, EsmonNL, EsmonCT. Histones induce phosphatidylserine exposure and a procoagulant phenotype in human red blood cells. J Thromb Haemost. 2014;12(10):1697–702.
66.
WautierMP, HeronE, PicotJ, ColinY, HermineO, WautierJL. Red blood cell phosphatidylserine exposure is responsible for increased erythrocyte adhesion to endothelium in central retinal vein occlusion. J Thromb Haemost. 2011;9(5):1049–55.
67.
LangF, QadriSM. Mechanisms and significance of eryptosis, the suicidal death of erythrocytes. Blood Purif. 2012;33(1-3):125–30.
68.
WestermanM, PizzeyA, HirschmanJ, CerinoM, Weil-WeinerY, RamotarP, et al. Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. British Journal of Haematology. 2008;142(1):126–35.
69.
WhelihanMF, ZacharyV, OrfeoT, MannKG. Prothrombin activation in blood coagulation: The erythrocyte contribution to thrombin generation. Blood. 2012;120(18):3837–45.
70.
AtagaKI, MooreCG, HilleryCA, JonesS, WhinnaHC, StrayhornD, et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica. 2008;93(1):20–6.
71.
StuartMJ, SettyBN. Hemostatic alterations in sickle cell disease: Relationships to disease pathophysiology. Pediatric Pathology & Molecular Medicine. 2001;20(1):27–46.
72.
ButenasS, BrandaRF, van’t VeerC, CawthernKM, MannKG. Platelets and phospholipids in tissue factor-initiated thrombin generation. Thrombosis and haemostasis. 2001;86(2):660–7.
73.
SettyBN, KulkarniS, RaoAK, StuartMJ. Fetal hemoglobin in sickle cell disease: Relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood. 2000;96(3):1119–24.
74.
GarridoVT, Proenca-FerreiraR, DominicalVM, TrainaF, BezerraMA, de MelloMR, et al. Elevated plasma levels and platelet-associated expression of the pro-thrombotic and pro-inflammatory protein, TNFSF14 (LIGHT), in sickle cell disease. British Journal of Haematology. 2012;158(6):788–97.
75.
KennyMW, GeorgeAJ, StuartJ. Platelet hyperactivity in sickle-cell disease: A consequence of hyposplenism. Journal of Clinical Pathology. 1980;33(7):622–5.
76.
LeeSP, AtagaKI, OrringerEP, PhillipsDR, PariseLV. Biologically active CD40 ligand is elevated in sickle cell anemia: Potential role for platelet-mediated inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26(7):1626–31.
77.
WestwickJ, Watson-WilliamsEJ, KrishnamurthiS, MarksG, EllisV, ScullyMF, et al. Platelet activation during steady state sickle cell disease. J Med. 1983;14(1):17–36.
78.
WunT, PaglieroniT, RangaswamiA, FranklinPH, WelbornJ, CheungA, et al. Platelet activation in patients with sickle cell disease. British Journal of Haematology. 1998;100(4):741–9.
79.
WunT, PaglieroniT, TablinF, WelbornJ, NelsonK, CheungA. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. The Journal of Laboratory and Clinical Medicine. 1997;129(5):507–16.
80.
VillagraJ, ShivaS, HunterLA, MachadoRF, GladwinMT, KatoGJ. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood. 2007;110(6):2166–72.
81.
HelmsCC, MarvelM, ZhaoW, StahleM, VestR, KatoGJ, et al. Mechanisms of hemolysis-associated platelet activation. J Thromb Haemost. 2013;11(12):2148–54.
82.
WajihN, BasuS, JailwalaA, KimHW, OstrowskiD, PerlegasA, et al. Potential therapeutic action of nitrite in sickle cell disease. Redox Biol. 2017;12:1026–39.
83.
LindmarkE, TennoT, SiegbahnA. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20(10):2322–8.
84.
GarridoVT, SonzogniL, MtatiroSN, CostaFF, ConranN, TheinSL. Association of plasma CD40L with acute chest syndrome in sickle cell anemia. Cytokine. 2017;97:104–7.
85.
ConranN, ReesDC. Prasugrel hydrochloride for the treatment of sickle cell disease. Expert Opin Investig Drugs. 2017;26(7):865–72.
86.
NoubouossieD, KeyNS, AtagaKI. Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies. Blood Reviews. 2016;30(4):245–56.
87.
TelenMJ. Developing new pharmacotherapeutic approaches to treating sickle-cell disease. ISBT Sci Ser. 2017;12(1):239–47.
88.
WunT, BrunsonA. Sickle cell disease: An inherited thrombophilia. Hematology/the Education Program of the American Society of Hematology. 2016(1):640–7.
89.
Proenca-FerreiraR, Franco-PenteadoCF, TrainaF, SaadST, CostaFF, ConranN. Increased adhesive properties of platelets in sickle cell disease: Roles for alphaIIb beta3-mediated ligand binding, diminished cAMP signalling and increased phosphodiesterase 3A activity. British Journal of Haematology. 2010;149(2):280–8.
90.
LeeSP, AtagaKI, ZayedM, ManganelloJM, OrringerEP, PhillipsDR, et al. Phase I study of eptifibatide in patients with sickle cell anaemia. British Journal of Haematology. 2007;139(4):612–20.
91.
DesaiPC, BrittainJE, JonesSK, McDonaldA, WilsonDR, DominikR, et al. A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. Thromb Res. 2013;132(3):341–5.
92.
FrelingerAL, 3rdJakubowskiJA, BrooksJK, CarmichaelSL, Berny-LangMA, BarnardMR, et al. Platelet activation and inhibition in sickle cell disease (pains) study. Platelets. 2014;25(1):27–35.
93.
MoserBA, LaBellES, ChigutsaE, JakubowskiJA, SmallDS. Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia. Clin Pharmacokinet. 2017.
94.
WunT, SoulieresD, FrelingerAL, KrishnamurtiL, NovelliEM, KutlarA, et al. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol. 2013;6:17.
95.
HeeneyMM, HoppeCC, AbboudMR, InusaB, KanterJ, OgutuB, et al. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. The New England Journal of Medicine. 2016;374(7):625–35.
96.
el-HazmiMA, WarsyAS, BahakimH. Blood proteins C and S in sickle cell disease. Acta Haematologica. 1993;90(3):114–9.
97.
BayazitAK, KilincY. Natural coagulation inhibitors (protein C, protein S, antithrombin) in patients with sickle cell anemia in a steady state. Pediatr Int. 2001;43(6):592–6.
98.
LiesnerR, MackieI, CooksonJ, McDonaldS, ChitolieA, DonohoeS, et al. Prothrombotic changes in children with sickle cell disease: Relationships to cerebrovascular disease and transfusion. British Journal of Haematology. 1998;103(4):1037–44.
99.
PiccinA, MurphyC, EakinsE, KinsellaA, McMahonC, SmithOP, et al. Protein C and free protein S in children with sickle cell anemia. Annals of Hematology. 2012;91(10):1669–71.
100.
TamDA. Protein C and protein S activity in sickle cell disease and stroke. J Child Neurol. 1997;12(1):19–21.
101.
GriffinJH, ZlokovicBV, MosnierLO. Activated protein C: Biased for translation. Blood. 2015;125(19):2898–907.
102.
BezeaudA, VenisseL, HelleyD, TrichetC, GirotR, GuillinMC. Red blood cells from patients with homozygous sickle cell disease provide a catalytic surface for factor Va inactivation by activated protein C. British Journal of Haematology. 2002;117(2):409–13.
103.
GavinsFN, RussellJ, SenchenkovaEL, De Almeida PaulaL, DamazoAS, EsmonCT, et al. Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-S. Blood. 2011;117(15):4125–33.
104.
MosnierLO, ZlokovicBV, GriffinJH. The cytoprotective protein C pathway. Blood. 2007;109(8):3161–72.
105.
LanePA, O’ConnellJL, MarlarRA. Erythrocyte membrane vesicles and irreversibly sickled cells bind protein S. American Journal of Hematology. 1994;47(4):295–300.
106.
ChekkalM, RahalMCA, MoulasserdounK, SeghierF. Increased level of factor VIII and physiological inhibitors of coagulation in patients with sickle cell disease. Indian J Hematol Blood Transfus. 2017;33(2):235–8.
107.
WrightJG, MaliaR, CooperP, ThomasP, PrestonFE, SerjeantGR. Protein C and protein S in homozygous sickle cell disease: Does hepatic dysfunction contribute to low levels?British Journal of Haematology. 1997;98(3):627–31.
108.
ColombattiR, De BonE, BertomoroA, CasonatoA, PontaraE, OmenettoE, et al. Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy. PLoS One. 2013;8(10):e78801.
109.
GuptaS, CarmonaR, MalvarJ, YoungG. Thromboelastographic characterization of the activated clotting system in children with sickle cell trait or sickle cell disease. Thromb Res. 2017;151:44–50.
110.
HebbelRP. Adhesion of sickle red cells to endothelium: Myths and future directions. Transfus Clin Biol. 2008;15(1-2):14–8.
111.
KaulDK, FabryME. In vivo studies of sickle red blood cells. Microcirculation. 2004;11(2):153–65.
112.
ConnesP, AlexyT, DetterichJ, RomanaM, Hardy-DessourcesMD, BallasSK. The role of blood rheology in sickle cell disease. Blood Reviews. 2016;30(2):111–8.
113.
ConnesP, LamarreY, WaltzX, BallasSK, LemonneN, Etienne-JulanM, et al. Haemolysis and abnormal haemorheology in sickle cell anaemia. British Journal of Haematology. 2014;165(4):564–72.
114.
KatoGJ, SteinbergMH, GladwinMT. Intravascular hemolysis and the pathophysiology of sickle cell disease. The Journal of Clinical Investigation. 2017;127(3):750–60.
115.
HebbelRP. Ischemia-reperfusion injury in sickle cell anemia: Relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain. Hematology/Oncology Clinics of North America. 2014;28(2):181–98.
116.
ChiricoEN, PialouxV. Role of oxidative stress in the pathogenesis of sickle cell disease. International Union of Biochemistry and Molecular Biology. 2012;64(1):72–80.
117.
HilleryC, FosterTD, HolzhauerSL, ScottJP, PanepintoJA, MohandasN, MackmanN, WanderseeNJ. Tissue factor deficiency decreases sickle cell-induced vascular stasis in a hematopoietic stem cell transplant model of murine sickle cell disease. Blood. 2004;104:236.
SparkenbaughEM, ChantrathammachartP, MickelsonJ, van RynJ, HebbelRP, MonroeDM, et al. Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood. 2014;123(11):1747–56.
121.
BallasSK, MarcolinaMJ. Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. Transfusion. 2006;46(1):105–10.
122.
CardenesN, CoreyC, GearyL, JainS, ZharikovS, BargeS, et al. Platelet bioenergetic screen in sickle cell patients reveals mitochondrial complex V inhibition, which contributes to platelet activation. Blood. 2014;123(18):2864–72.
BelcherJD, ChenC, NguyenJ, MilbauerL, AbdullaF, AlayashAI, et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2014;123(3):377–90.
125.
GhoshS, AdisaOA, ChappaP, TanF, JacksonKA, ArcherDR, et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. The Journal of Clinical Investigation. 2013;123(11):4809–20.
126.
VinchiF, Costa da SilvaM, IngogliaG, PetrilloS, BrinkmanN, ZuercherA, et al. Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease. Blood. 2016;127(4):473–86.
127.
HebbelRP, KeyNS. Microparticles in sickle cell anaemia: Promise and pitfalls. British Journal of Haematology. 2016;174(1):16–29.
128.
Rehani TMK, BelcherJD, VercellottiGM, SlungaardA. Heme potently stimulates tissue factor expression by peripheral blood monocytes: A novel mechanism for thrombosis in intravascular hemolytic diseases. Blood. 2013;122:2215.
129.
SettyBN, BetalSG, ZhangJ, StuartMJ. Heme induces endothelial tissue factor expression: Potential role in hemostatic activation in patients with hemolytic anemia. J Thromb Haemost. 2008;6(12):2202–9.
130.
VinchiF, De FranceschiL, GhigoA, TownesT, CiminoJ, SilengoL, et al. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases. Circulation. 2013;127(12):1317–29.
131.
de SouzaGR, HounkpeBW, FiusaMML, ColellaMP, Annichino-BizzacchiJM, TrainaF, et al. Tissue factor-dependent coagulation activation by heme: A thromboelastometry study. PLoS One. 2017;12(4):e0176505.
132.
ChapinJ, TerryHS, KleinertD, LaurenceJ. The role of complement activation in thrombosis and hemolytic anemias. Transfus Apher Sci. 2016;54(2):191–8.
133.
RoumeninaLT, RayesJ, Lacroix-DesmazesS, DimitrovJD. Heme: Modulator of plasma systems in Hemolytic diseases. Trends Mol Med. 2016;22(3):200–13.
134.
BrinkmannV, ZychlinskyA. Beneficial suicide: Why neutrophils die to make NETs. Nat Rev Microbiol. 2007;5(8):577–82.
135.
FuchsTA, AbedU, GoosmannC, HurwitzR, SchulzeI, WahnV, et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol. 2007;176(2):231–41.
136.
SaffarzadehM, JuenemannC, QueisserMA, LochnitG, BarretoG, GaluskaSP, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: A predominant role of histones. PLoS One. 2012;7(2):e32366.
137.
BrillA, FuchsTA, SavchenkoAS, ThomasGM, MartinodK, De MeyerSF, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2012;10(1):136–44.
138.
FuchsTA, BrillA, WagnerDD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2012;32(8):1777–83.
139.
ShimmerC, HamoudaK, OzkurM, SommerSP, HainJ, AleksicI, et al. Influence of storage time and amount of red blood cell transfusion on postoperative renal function: An observational cohort study. Heart Lung Vessel. 2013;5(3):148–57.
140.
CamusSM, De MoraesJA, BonninP, AbbyadP, Le JeuneS, LionnetF, et al. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. Blood. 2015;125(24):3805–14.
141.
KasarM, BogaC, YeralM, AsmaS, KozanogluI, OzdoguH. Clinical significance of circulating blood and endothelial cell microparticles in sickle-cell disease. Journal of Thrombosis and Thrombolysis. 2014;38(2):167–75.
142.
ShetAS, ArasO, GuptaK, HassMJ, RauschDJ, SabaN, et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood. 2003;102(7):2678–83.
143.
van TitsLJ, van HeerdeWL, LandburgPP, BoderieMJ, MuskietFA, JacobsN, et al. Plasma annexin A5 and microparticle phosphatidylserine levels are elevated in sickle cell disease and increase further during painful crisis. Biochemical and Biophysical Research Communications. 2009;390(1):161–4.
144.
NouraieM, LeeJS, ZhangY, KaniasT, ZhaoX, XiongZ, et al. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica. 2013;98(3):464–72.
145.
HiersoR, LemonneN, VillaescusaR, Lalanne-MistrihML, CharlotK, Etienne-JulanM, et al. Exacerbation of oxidative stress during sickle vaso-occlusive crisis is associated with decreased anti-band 3 autoantibodies rate and increased red blood cell-derived microparticle level: A prospective study. British Journal of Haematology. 2017;176(5):805–13.
146.
NeborD, RomanaM, SantiagoR, VachieryN, PicotJ, BroquereC, et al. Fetal hemoglobin and hydroxycarbamide moduate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children. Haematologica. 2013;98(6):862–7.
147.
TantawyAA, AdlyAA, IsmailEA, HabeebNM, FaroukA. Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: Relation to cardiovascular complications. Platelets. 2013;24(8):605–14.
148.
WestermanM, PorterJB. Red blood cell-derived microparticles: An overview. Blood cells, molecules & diseases. 2016;59:134–9.
149.
BrunettaDM, De SantisGC, Silva-PintoAC, Oliveira de OliveiraLC, CovasDT. Hydroxyurea increases plasma concentrations of microparticles and reduces coagulation activation and fibrinolysis in patients with sickle cell anemia. Acta Haematologica. 2015;133(3):287–94.
150.
GerotziafasGT, Van DredenP, ChaariM, GaleaV, KhaterchiA, LionnetF, et al. The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles. Thrombosis and Haemostasis. 2012;107(6):1044–52.
151.
GarnierY, FerdinandS, ConnesP, GarnierM, Etienne-JulanM, LemonneN, et al. Decrease of externalized phosphatidylserine density on red blood cell-derived microparticles in SCA patients treated with hydroxycarbamide. British Journal of Haematology. 2017.
152.
ByrnesJR, DuvalC, WangY, HansenCE, AhnB, MooberryMJ, et al. Factor XIIIa-dependent retention of red blood cells in clots is medidated by fibrin alpha-chain crosslinking. Blood. 2015;126(16):1940–8.
153.
AverettRD, NortonDG, FanNK, PlattMO. Computational imaging analysis of fibrin matrices with the inclusion of erythrocytes from homozygous SS blood reveals agglomerated and amorphous structures. Journal of Thrombosis and Thrombolysis. 2017;43(1):43–51.
154.
Ohene-FrempongK, WeinerSJ, SleeperLA, MillerST, EmburyS, MoohrJW, et al. Cerebrovascular accidents in sickle cell disease: Rates and risk factors. Blood. 1998;91(1):288–94.
155.
AdamsR, McKieV, NicholsF, CarlE, ZhangDL, McKieK, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. The New England Journal of Medicine. 1992;326(9):605–10.
156.
HyacinthHI, AdamsRJ, GreenbergCS, VoeksJH, HillA, HibbertJM, et al. Effect of chronic blood transfusion on biomarkers of coagulation activation and thrombin generation in sickle cell patients at risk for stroke. PLoS One. 2015;10(8):e0134193.
157.
NoubouossieDC, LePQ, RozenL, ZiereisenF, WillemsD, DemulderA, et al. Thrombin generation in children with sickle cell disease: Relationship with age, hemolysis, transcranial Doppler velocity, and hydroxyurea treatment. European Journal of Haematology. 2013;91(1):46–54.
158.
StrouseJJ, JordanLC, LanzkronS, CasellaJF. The excess burden of stroke in hospitalized adults with sickle cell disease. American Journal of Hematology. 2009;84(9):548–52.
159.
ShahN, ThornburgC, TelenMJ, OrtelTL. Characterization of the hypercoagulable state in patients with sickle cell disease. Thromb Res. 2012;130(5):e241–5.
160.
MackAK, ThompsonAA. Primary and secondary stroke prevention in children with sickle cell disease. J Pediatr Health Care. 2017;31(2):145–54.
161.
Redding-LallingerR, KnollC. Sickle cell disease–pathophysiology and treatment. Curr Probl Pediatr Adolesc Health Care. 2006;36(10):346–76.
162.
DeBaunMR, ArmstrongFD, McKinstryRC, WareRE, VichinskyE, KirkhamFJ. Silent cerebral infarcts: A review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood. 2012;119(20):4587–96.
163.
QuinnCT. Breakthrough: New guidance for silent cerebral ischemia and infarction in sickle cell disease. Hematology/the Education Program of the American Society of Hematology. 2014;2014(1):438–43.
164.
BernaudinF, VerlhacS, ArnaudC, KamdemA, ChevretS, HauI, et al. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood. 2011;117(4):1130–40; quiz 436.
165.
LanceEI, CasellaJF, EverettAD, Barron-CasellaE. Proteomic and biomarker studies and neurological complications of pediatric sickle cell disease. Proteomics Clin Appl. 2014;8(11-12):813–27.
166.
van Hamel ParsonsV, GardnerK, PatelR, TheinSL. Venous thromboembolism in adults with sickle cell disease: Experience of a single centre in the UK. Annals of hematology. 2016;95(2):227–32.
167.
KoRH, ThornburgCD. Venous Thromboembolism in Children with Cancer and Blood Disorders. Front Pediatr. 2017;5:12.
168.
HeitJA, KobbervigCE, JamesAH, PettersonTM, BaileyKR, MeltonLJ. 3rdTrends in the incidence of venous thromboembolism during pregnancy or postpartum: A 30-year population-based study. Annals of Internal Medicine. 2005;143(10):697–706.
169.
SeamanCD, YabesJ, LiJ, MooreCG, RagniMV. Venous thromboembolism in pregnant women with sickle cell disease: A retrospective database analysis. Thromb Res. 2014;134(6):1249–52.
170.
NaikRP, StreiffMB, LanzkronS. Sickle cell disease and venous thromboembolism: What the anticoagulation expert needs to know. Journal of Thrombosis and Thrombolysis. 2013;35(3):352–8.
171.
Tiago de Oliveira Boechat EMdN Clarisse lopes de Castro Lobo and Ballas SK. Deep venous thrombosis in children with sickle cell disease. Pediatric Blood & Cancer. 2015;62(5):838–41.
172.
YuTT, NelsonJ, StreiffMB, LanzkronS, NaikRP. Risk factors for venous thromboembolism in adults with hemoglobin SC or Sbeta(+) thalassemia genotypes. Thromb Res. 2016;141:35–8.
173.
HauptHM, MooreGW, BauerTW, HutchinsGM. The lung in sickle cell disease. Chest. 1982;81(3):332–7.
174.
OppenheimerEH, EsterlyJRPulmonary changes in sickle cell disease. Am Rev Respir Dis. 1971;103(6):858–9.
175.
NovelliEM, HuynhC, GladwinMT, MooreCG, RagniMV. Pulmonary embolism in sickle cell disease: A case-control study. J Thromb Haemost. 2012;10(5):760–6.
176.
SparkenbaughE, FaesC, NoubouossieD, KirchhoferDK, GruberA, KeyNS, et al. FXIIa differentially regulates thrombin generation during steady state and vaso-occlusive crisis in sickle cell mice. Blood. 2016;128:162.
177.
WeitzJI. Factor XI and factor XII as targets for new anticoagulants. Thromb Res. 2016;141(Suppl 2):S40–5.
178.
AllanD, LimbrickAR, ThomasP, WestermanMP. Release of spectrin-free spicules on reoxygenation of sickled erythrocytes. Nature. 1982;295(5850):612–3.
179.
BaskurtOK, BoynardM, CokeletGC, ConnesP, CookeBM, ForconiS, et al. New guidelines for hemorheological laboratory techniques. Clinical Hemorheology and Microcirculation. 2009;42(2):75–97.
